Normal SLCO1B1 transporter function. Normal myopathy risk expected based on SLCO1B1 alone.
Important Instructions: Please use CYP2C9 phenotype to select the appropriate recommendation below.
CYP2C9 Normal Metabolizer
Normal CYP2C9 enzyme activity. Normal response expected based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate standard dosing.
CYP2C9 Intermediate Metabolizer
Decreased CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate ≤ 40 mg, if a dose >40 mg is needed, consider alternative statin or combination therapy.
CYP2C9 Poor Metabolizer
Little to no CYP2C9 enzyme activity. Potential for increased risk of myopathy based on CYP2C9 alone.
Therapeutic Recommendation
- Initiate ≤ 20 mg, if a dose >20 mg is needed, consider alternative statin or combination therapy.